INC. (NASDAQ:INCR) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On January 21, 2021, we issued the press release furnished herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press Release issued January 21, 2021|
Red Cat Holdings, Inc. Exhibit
EX-99.1 2 rcat0122form8kexh99_1.htm EXHIBIT 99.1 Exhibit 99.1 Red Cat to Host Investor Update Call on January 25 at 4:15 pm ET ORLANDO,…
To view the full exhibit click
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.